Trametinib for progressive pediatric low-grade gliomas.

Maria KondyliValérie LaroucheChristine Saint-MartinBenjamin EllezamLauranne PouliotDaniel SinnettGeneviève LegaultLouis CrevierAlex WeilJean-Pierre FarmerNada JabadoSébastien Perreault

Published in: Journal of neuro-oncology (2018)

Trametinib appears to be a suitable option for refractory pediatric low-grade glioma and warrants further investigations in case of progression.

Keyphrases

low grade
high grade
multiple sclerosis
young adults